export type LinkPart = {
  href: string;
  text: string;
  external?: boolean;   // if true, render <a target="_blank" rel>
  sponsored?: boolean;  // if true, append "sponsored" to rel
};

export type Part = string | LinkPart;

export type Section = {
  type: "intro" | "h2" | "h3" | "p" | "ul" | "callout" | "cta" | "disclaimer" | "faq";
  text?: string;
  items?: string[];
  productSlug?: string;
  vendor?: string;
  affiliateUrl?: string;
  parts?: Part[];
  faq?: Array<{ q: string; a: string }>;
};

export type Post = {
  slug: string;
  title: string;
  excerpt: string;
  category: string;
  date: string;
  readTime: string;
  content: Section[];
  wordCount?: number;
  lastUpdated?: string;
};

export const posts: Post[] = [
  {
    slug: "peptide-protocol-cheat-sheet",
    title: "Peptide Protocol Cheat Sheet: Quick-Reference Guide for Researchers",
    excerpt:
      "All 11 compounds on Aura Protocols — mechanism, category, research status, and key differentiators — in one scannable reference.",
    category: "Buyer's Guide",
    date: "June 2026",
    readTime: "10 min read",
    content: [
      {
        type: "intro",
        text: "This cheat sheet covers every compound currently featured on Aura Protocols — organized by research category, with the key mechanism, studied effects, and differentiators you need to compare them at a glance. Each entry is a compressed summary; click through to the full product page or deep-dive article for complete literature breakdowns.",
      },
      {
        type: "h2",
        text: "Recovery & Tissue Repair",
      },
      {
        type: "h3",
        text: "BPC-157 (Body Protection Compound-157)",
      },
      {
        type: "ul",
        items: [
          "Class: Synthetic pentadecapeptide derived from human gastric juice",
          "Mechanism: Upregulates growth hormone receptors in tendon fibroblasts; modulates nitric oxide production; promotes angiogenesis at injury sites",
          "Primary research areas: Tendon/ligament repair, gut mucosal healing, anti-inflammatory effects, neuroprotection",
          "Administration routes studied: Subcutaneous, intramuscular, oral/intragastric, topical",
          "Key differentiator: One of few peptides with gut-specific preclinical data; stable in gastric acid",
          "Research status: Extensive rodent models, no completed human RCTs",
        ],
      },
      {
        type: "h3",
        text: "TB-500 (Thymosin Beta-4)",
      },
      {
        type: "ul",
        items: [
          "Class: Synthetic analogue of endogenous Thymosin Beta-4",
          "Mechanism: Promotes actin polymerization; accelerates cell migration to injury sites; stimulates new blood vessel formation",
          "Primary research areas: Wound healing, cardiac tissue repair, tendon and muscle recovery, anti-fibrotic effects",
          "Administration routes studied: Subcutaneous, intravenous (preclinical)",
          "Key differentiator: Systemic distribution via blood vessel recruitment — can act at sites distant from injection",
          "Research status: Phase I/II human trials for cardiac repair; broader applications remain preclinical",
        ],
      },
      {
        type: "cta",
        text: "View BPC-157 at Limitless Life Nootropics",
        productSlug: "bpc-157",
        vendor: "Limitless Life Nootropics",
        affiliateUrl: "https://limitlesslifenootropics.com/product/bpc-157?uid=17&oid=1&affid=10866",
      },
      {
        type: "h2",
        text: "Weight Management & Metabolic Research",
      },
      {
        type: "h3",
        text: "Semaglutide",
      },
      {
        type: "ul",
        items: [
          "Class: GLP-1 receptor agonist",
          "Mechanism: Slows gastric emptying; suppresses appetite via hypothalamic GLP-1R activation; stimulates glucose-dependent insulin secretion",
          "Primary research areas: Obesity, type 2 diabetes, cardiovascular risk reduction",
          "Key data: STEP trials — avg 15–17% body weight reduction over 68 weeks; SELECT trial — 20% reduction in major adverse cardiovascular events",
          "Key differentiator: The most clinically documented peptide for weight loss; FDA approved as Ozempic (T2D) and Wegovy (obesity)",
          "Research status: Multiple large-scale RCTs completed; most evidence-backed compound in this category",
        ],
      },
      {
        type: "h3",
        text: "Retatrutide",
      },
      {
        type: "ul",
        items: [
          "Class: Triple agonist — GLP-1R, GIPR, and glucagon receptor",
          "Mechanism: Combines GLP-1 appetite suppression + GIP metabolic signaling + glucagon-driven energy expenditure",
          "Primary research areas: Severe obesity, metabolic syndrome",
          "Key data: Phase II SURMOUNT trial — up to 24% body weight reduction over 48 weeks; most potent weight loss signal of any peptide in clinical trials to date",
          "Key differentiator: Triple receptor engagement produces additive effects not seen in dual agonists; investigational only",
          "Research status: Phase III trials underway (2026); not yet FDA approved",
        ],
      },
      {
        type: "h3",
        text: "AOD-9604",
      },
      {
        type: "ul",
        items: [
          "Class: Synthetic C-terminal fragment of human growth hormone (hGH176–191)",
          "Mechanism: Stimulates fat breakdown (lipolysis) via β3-adrenergic receptors; inhibits new fat formation (lipogenesis) without affecting IGF-1 or blood glucose",
          "Primary research areas: Adipose tissue reduction, metabolic health",
          "Key differentiator: Isolated fat-loss mechanism with none of the anabolic or diabetogenic effects of full hGH — arguably the cleanest GH-derived fat loss research compound",
          "Research status: Human Phase IIb trial (Metabolic Pharmaceuticals) — statistically significant fat loss, development halted for commercial reasons not safety",
        ],
      },
      {
        type: "cta",
        text: "View Semaglutide at GLP-1 Research Lab",
        productSlug: "semaglutide",
        vendor: "GLP-1 Research Lab",
        affiliateUrl: "https://glp1researchlab.com/product/glp-1-semaglutide-2?aff=84",
      },
      {
        type: "h2",
        text: "Growth & Performance",
      },
      {
        type: "h3",
        text: "CJC-1295 / Ipamorelin (Stack)",
      },
      {
        type: "ul",
        items: [
          "Class: GHRH analogue (CJC-1295) + selective ghrelin receptor agonist (Ipamorelin)",
          "Mechanism: CJC-1295 raises baseline GH via GHRH receptor; Ipamorelin amplifies individual GH pulses via GHSR — dual-axis stimulation produces synergistic effect",
          "Primary research areas: Lean mass, visceral fat reduction, bone density, sleep quality, recovery",
          "Key differentiator: Ipamorelin does not elevate cortisol or prolactin — cleaner GH stimulation than GHRP-2/GHRP-6; preserves physiological pulsatile rhythm unlike exogenous GH",
          "Research status: Strong preclinical base; Ipamorelin had Phase II human trials (Novo Nordisk, for GI motility)",
        ],
      },
      {
        type: "h3",
        text: "Sermorelin",
      },
      {
        type: "ul",
        items: [
          "Class: GHRH analogue (first 29 amino acids of endogenous GHRH)",
          "Mechanism: Binds pituitary GHRH receptors to stimulate natural GH pulse; shorter half-life than CJC-1295 (~10–20 min vs. 6–8 days with DAC)",
          "Primary research areas: Age-related GH decline, body composition, hormonal restoration",
          "Key differentiator: FDA approved (1997, withdrawn for commercial reasons) — one of the best-characterized GHRH analogues; often studied in older populations with blunted GH secretion",
          "Research status: Historical clinical trials completed; widely documented in age management literature",
        ],
      },
      {
        type: "h3",
        text: "Tesamorelin",
      },
      {
        type: "ul",
        items: [
          "Class: Synthetic GHRH analogue (stabilized full-length GHRH1–44)",
          "Mechanism: Binds pituitary GHRH receptors; more potent GH stimulation than Sermorelin due to full-length sequence; preferential effect on visceral adipose tissue",
          "Primary research areas: HIV-associated lipodystrophy, visceral adiposity, cardiovascular risk markers",
          "Key differentiator: FDA approved as Egrifta for HIV-related belly fat — the only GHRH analogue with full regulatory approval and confirmed visceral fat reduction in humans",
          "Research status: Phase III RCTs completed; approved 2010, Egrifta SV approved 2019",
        ],
      },
      {
        type: "cta",
        text: "View CJC-1295 / Ipamorelin at Limitless Life Nootropics",
        productSlug: "cjc-1295-ipamorelin",
        vendor: "Limitless Life Nootropics",
        affiliateUrl: "https://limitlesslifenootropics.com/product/ipamorelin-cjc-1295-no-dac?uid=27&oid=1&affid=10866",
      },
      {
        type: "h2",
        text: "Wellness & Longevity",
      },
      {
        type: "h3",
        text: "PT-141 (Bremelanotide)",
      },
      {
        type: "ul",
        items: [
          "Class: Melanocortin receptor agonist (MC3R / MC4R)",
          "Mechanism: Acts centrally in the hypothalamus — initiates arousal via neurological cascade, not vascular dilation; dopaminergic + oxytocinergic pathway activation",
          "Primary research areas: Hypoactive sexual desire disorder (HSDD), erectile dysfunction (neurogenic), female sexual arousal disorder",
          "Key differentiator: Only sexual health peptide with a direct FDA approval pathway — approved as Vyleesi (2019) for HSDD in premenopausal women; unique central (non-vascular) mechanism",
          "Research status: RECONNECT trials (1,200+ women) completed; multiple Phase II trials in men",
        ],
      },
      {
        type: "h3",
        text: "Epithalon (Epitalon)",
      },
      {
        type: "ul",
        items: [
          "Class: Synthetic tetrapeptide (Ala-Glu-Asp-Gly)",
          "Mechanism: Stimulates pineal gland melatonin production; activates telomerase enzyme to slow telomere shortening; antioxidant and circadian rhythm modulation",
          "Primary research areas: Longevity, circadian dysregulation, telomere biology, age-related hormonal decline",
          "Key differentiator: Developed in the 1980s by the St. Petersburg Institute of Bioregulation — one of the longest-studied longevity peptides with 30+ years of Russian clinical data",
          "Research status: Predominantly Russian-language clinical literature; limited Western RCT base",
        ],
      },
      {
        type: "h3",
        text: "MOTS-c",
      },
      {
        type: "ul",
        items: [
          "Class: Mitochondria-derived peptide (encoded in mitochondrial 12S rRNA)",
          "Mechanism: Activates AMPK pathway; regulates glucose and lipid metabolism; reduces oxidative stress; improves insulin sensitivity",
          "Primary research areas: Metabolic syndrome, exercise performance, insulin resistance, aging",
          "Key differentiator: Discovered 2015 — one of the newest peptides on this list; endogenous origin (your own mitochondria produce it) distinguishes it from synthetic analogues; levels decline with age",
          "Research status: Preclinical (primarily rodent and cell studies); human trials emerging",
        ],
      },
      {
        type: "cta",
        text: "View PT-141 at Swiss Chems",
        productSlug: "pt-141",
        vendor: "Swiss Chems",
        affiliateUrl: "https://swisschems.is/product/pt-141-10mg-price-is-per-vial/?ref=6782",
      },
      {
        type: "h2",
        text: "How to Use This Reference",
      },
      {
        type: "p",
        text: "The most common research design errors come from selecting a compound based on desired outcome alone without accounting for mechanism specificity. A few rules of thumb that emerge from this table:",
      },
      {
        type: "ul",
        items: [
          "Mechanism before compound — identify which biological pathway you're targeting, then select the compound that engages it most precisely",
          "Regulatory history matters — FDA approvals (Tesamorelin, PT-141, Semaglutide) signal human safety data exists at therapeutic doses; compounds without that history require more conservative study design",
          "GH secretagogues are not interchangeable — Sermorelin, CJC-1295, and Tesamorelin all stimulate GH via GHRH receptors but have meaningfully different half-lives, potency, and clinical data sets",
          "Central vs. peripheral matters for sexual health — PT-141 operates upstream of PDE5 inhibitors; combining them targets different nodes of the same pathway",
          "Recovery compounds differ in systemic vs. local action — BPC-157 has a strong local effect; TB-500 distributes systemically via vasculature and is better suited to diffuse or multi-site injury models",
        ],
      },
      {
        type: "callout",
        text: "All compounds on this page are for research purposes only. They are not approved for human use outside of specific FDA-approved formulations under medical supervision. This reference does not constitute medical advice.",
      },
      {
        type: "faq",
        faq: [
          {
            q: "Which peptide has the strongest clinical evidence?",
            a: "Semaglutide, by a significant margin. It has completed Phase III RCTs in tens of thousands of subjects, has two FDA approvals, and multiple large-scale cardiovascular outcome trials. Tesamorelin and PT-141 are the next best-evidenced, each with FDA approval in a specific indication. Most others remain at the preclinical or Phase I/II stage.",
          },
          {
            q: "What's the difference between a GHRH analogue and a GHSR agonist?",
            a: "GHRH analogues (Sermorelin, CJC-1295, Tesamorelin) bind pituitary GHRH receptors to stimulate GH release from the pituitary's own stores. GHSR agonists (Ipamorelin) bind ghrelin receptors to amplify GH pulse amplitude. They act on different receptors within the GH axis, which is why combining them (CJC-1295 + Ipamorelin) produces a synergistic effect greater than either alone.",
          },
          {
            q: "Can recovery peptides and GH secretagogues be stacked?",
            a: "In research design, compounds with non-overlapping mechanisms are commonly studied together. BPC-157 (tissue repair via angiogenesis, NO modulation) and CJC-1295/Ipamorelin (GH axis stimulation) have distinct mechanisms with no documented pharmacological conflict. Stacking for research purposes should be approached with awareness of each compound's individual effect profile before combined study design is attempted.",
          },
          {
            q: "What does 'research use only' actually mean?",
            a: "Research-grade peptides from vendors like those featured on Aura Protocols are sold for laboratory and investigational use — not for human administration outside of supervised clinical settings. Purity standards, sterility, and regulatory oversight differ significantly from pharmaceutical-grade compounds. Buyers are responsible for understanding and complying with applicable laws in their jurisdiction.",
          },
          {
            q: "How do I choose between Semaglutide and Retatrutide for a weight loss study?",
            a: "Semaglutide is GLP-1 only with the most complete clinical literature. Retatrutide adds GIP and glucagon receptor engagement for a larger magnitude of effect — up to 24% weight loss vs. ~17% for semaglutide. If you're studying maximum weight reduction potential, Retatrutide's Phase II data is compelling. If you need a compound with the deepest existing evidence base, Semaglutide is the benchmark. Retatrutide remains investigational with Phase III ongoing.",
          },
        ],
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "pt-141-melanocortin-bremelanotide-guide",
    title:
      "PT-141 (Bremelanotide): Hypothalamic Activation, the Brain-to-Spine Arousal Cascade, and Post-RARP Research",
    excerpt:
      "How PT-141 binds MC3R and MC4R to initiate arousal centrally, why this matters for post-prostatectomy ED research, and the full melanocortin analog family from α-MSH to setmelanotide.",
    category: "Wellness",
    date: "June 2026",
    readTime: "12 min read",
    content: [
      {
        type: "intro",
        text: "PT-141, generically known as bremelanotide, occupies a distinct position in the peptide research landscape. Unlike the PDE5 inhibitors that dominate mainstream erectile dysfunction treatment, PT-141 doesn't act on vascular smooth muscle at all. It acts on the brain. This central mechanism — binding melanocortin receptors in the hypothalamus to initiate a neurological cascade rather than dilating blood vessels — is what makes PT-141 relevant to researchers studying populations where peripheral interventions consistently underperform. Among the most studied: men who have undergone radical prostatectomy for prostate cancer. This guide covers PT-141's mechanism of action at the receptor level, the clinical rationale for its use in post-surgical ED research, and where it sits within the broader melanocortin peptide family.",
      },
      {
        type: "h2",
        text: "How PT-141 Works: Melanocortin Receptor Binding",
      },
      {
        type: "p",
        text: "The melanocortin system is a network of five G-protein-coupled receptors (MC1R through MC5R), each with distinct tissue distribution and physiological roles. PT-141 demonstrates binding affinity primarily at MC3R and MC4R — the two subtypes most implicated in sexual function and autonomic regulation.",
      },
      {
        type: "h3",
        text: "MC4R: The Key Receptor for Sexual Function",
      },
      {
        type: "p",
        text: "MC4R is expressed densely in the paraventricular nucleus (PVN) of the hypothalamus, one of the brain's primary integration centers for sexual arousal, autonomic output, and hormone regulation. When PT-141 binds MC4R in the PVN, it triggers a downstream cascade involving activation of oxytocinergic neurons, dopaminergic pathway stimulation, and spinal cord signal propagation to the sacral parasympathetic nerves.",
      },
      {
        type: "ul",
        items: [
          "Activation of oxytocinergic neurons, which project to the spinal cord and influence penile erection and sexual motivation",
          "Dopaminergic pathway stimulation in the mesolimbic system, contributing to desire and arousal",
          "Spinal cord signal propagation to the sacral parasympathetic nerves, which ultimately drive engorgement",
        ],
      },
      {
        type: "h3",
        text: "The Critical Mechanistic Difference",
      },
      {
        type: "p",
        text: "Sildenafil (Viagra) and tadalafil (Cialis) inhibit phosphodiesterase type 5, an enzyme that breaks down cGMP in vascular smooth muscle. The result: vasodilation and increased blood flow to erectile tissue. But this mechanism depends entirely on an intact nerve signal arriving first. Without a functioning nerve pathway delivering nitric oxide to the tissue, there is no cGMP to preserve. PDE5 inhibitors have nothing to amplify. PT-141 bypasses this requirement. The signal originates above the peripheral nervous system — meaning it may retain efficacy in neurogenic ED where the downstream pathway is compromised, provided sufficient central connectivity remains.",
      },
      {
        type: "h2",
        text: "PT-141 in Post-RARP Research",
      },
      {
        type: "h3",
        text: "What RARP Does to Erectile Function",
      },
      {
        type: "p",
        text: "Robot-Assisted Radical Prostatectomy is the gold standard surgical intervention for localized prostate cancer. The procedure removes the prostate gland entirely, and in doing so, places the neurovascular bundles running alongside the prostate — the cavernous nerves — at significant risk. Even in nerve-sparing techniques, traction, thermal injury, and inflammation during surgery cause neurapraxia — a temporary (and sometimes permanent) disruption of nerve conduction.",
      },
      {
        type: "ul",
        items: [
          "Bilateral nerve-sparing: 54–70% ED rate at 12 months",
          "Unilateral nerve-sparing: 70–80% ED rate",
          "Non-nerve-sparing: >90% ED rate",
        ],
      },
      {
        type: "h3",
        text: "Why PDE5 Inhibitors Underperform Post-RARP",
      },
      {
        type: "p",
        text: "In the early post-RARP window, cavernous nerve conduction is impaired. The nitric oxide signal that PDE5 inhibitors depend on is absent or severely diminished. Multiple clinical studies have found that on-demand PDE5 inhibitor use produces a meaningful erection in only 30–40% of post-RP patients in the first year — significantly below the 60–80% response rates seen in vasculogenic ED.",
      },
      {
        type: "h3",
        text: "The Central Mechanism Argument",
      },
      {
        type: "p",
        text: "Because PT-141 initiates arousal centrally — via MC4R in the hypothalamus, projecting down through spinal cord pathways — it does not require an intact cavernous nerve signal at the peripheral level. Research on MC4R agonists in animal models of cavernous nerve injury has demonstrated that centrally-mediated erections can occur even after bilateral cavernous nerve resection, suggesting the spinal pathway retains independent function. Note: No large-scale RCTs have been published specifically evaluating PT-141 in post-RARP patients as of mid-2026. The mechanistic rationale is well-grounded, and melanocortin agonist research in neurogenic ED is an active area.",
      },
      {
        type: "h3",
        text: "Beyond Erection — Orgasmic Dysfunction Post-RARP",
      },
      {
        type: "p",
        text: "Prostatectomy eliminates ejaculation, but orgasm — the neurological event — persists in most patients, often described as qualitatively different. PT-141's dopaminergic and oxytocinergic effects on the reward pathway may be relevant to orgasm quality independent of erection. This remains a research-stage hypothesis.",
      },
      {
        type: "h2",
        text: "The Melanocortin Peptide Analog Family",
      },
      {
        type: "p",
        text: "α-MSH is a 13-amino acid peptide derived from pro-opiomelanocortin (POMC). It has broad melanocortin receptor affinity and regulates skin pigmentation (MC1R), energy homeostasis, inflammation, and sexual function (MC3R/MC4R). Its short half-life makes it impractical as a therapeutic agent — all synthetic analogs in this family were developed to address this limitation.",
      },
      {
        type: "h3",
        text: "Melanotan I — Afamelanotide (Scenesse)",
      },
      {
        type: "p",
        text: "MC1R-selective synthetic analog. FDA-approved 2019 for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme sun sensitivity. Produces skin darkening with minimal sexual side effects due to MC1R selectivity. Not studied for sexual function.",
      },
      {
        type: "h3",
        text: "Melanotan II (MT-II)",
      },
      {
        type: "p",
        text: "Non-selective cyclic analog developed in the early 1990s at the University of Arizona. Binds MC1R, MC3R, MC4R, and MC5R simultaneously — producing tanning, appetite suppression, and spontaneous erections as simultaneous effects. Researchers observed erection effects in clinical subjects before tanning was visible. High side effect burden (nausea, facial flushing, spontaneous erections) limited clinical viability. The foundational research compound from which PT-141 was derived.",
      },
      {
        type: "h3",
        text: "PT-141 / Bremelanotide (Vyleesi)",
      },
      {
        type: "p",
        text: "Derived from MT-II with modified structure to retain MC3R/MC4R selectivity while reducing MC1R activity. Substantially less tanning effect, preserved sexual arousal effects. FDA-approved 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting FDA-approved treatment for female sexual dysfunction. RECONNECT trials (1,200+ women): statistically significant improvement in satisfying sexual events and distress reduction vs placebo.",
      },
      {
        type: "h3",
        text: "Setmelanotide (Imcivree)",
      },
      {
        type: "p",
        text: "Highly MC4R-selective. FDA-approved 2020 for chronic weight management in genetic obesity caused by POMC, PCSK1, or LEPR deficiency. Demonstrates the MC4R pathway's established role in energy and appetite — the same pathway PT-141 engages for sexual function.",
      },
      {
        type: "h2",
        text: "PT-141 in Women's Research",
      },
      {
        type: "p",
        text: "The FDA approval of bremelanotide as Vyleesi for HSDD in premenopausal women is the clearest clinical validation of the melanocortin pathway in human sexual function to date. Most common adverse effects in trials: nausea (40%), flushing (20%), injection site reactions, transient blood pressure increases. These mirror the MT-II side effect profile and inform dosing caution in research contexts.",
      },
      {
        type: "callout",
        text: "PT-141 (bremelanotide) is available through research vendors for laboratory and investigational use only. It is not approved for the indications described above outside of the FDA-approved Vyleesi formulation, which requires a prescription. Nothing in this article constitutes medical advice. Consult a qualified physician for any therapeutic application.",
      },
      {
        type: "cta",
        text: "View PT-141 at Swiss Chems",
        productSlug: "pt-141",
        vendor: "Swiss Chems",
        affiliateUrl: "https://swisschems.is/product/pt-141-10mg-price-is-per-vial/?ref=6782",
      },
      {
        type: "faq",
        faq: [
          {
            q: "Why doesn't PT-141 cause tanning like Melanotan II?",
            a: "PT-141 has significantly reduced activity at MC1R — the receptor responsible for melanin production. This was a deliberate modification from MT-II, which stimulated all four receptor subtypes including MC1R. PT-141 retains functional selectivity toward MC3R and MC4R with minimal pigmentation effect.",
          },
          {
            q: "Can PT-141 work if Viagra doesn't?",
            a: "The mechanistic argument is yes — specifically in neurogenic ED where the peripheral nerve signal is compromised. PDE5 inhibitors require an intact nitric oxide signal from the cavernous nerve; PT-141 initiates arousal centrally and may bypass a damaged peripheral pathway. This is not established in large RCTs for post-prostatectomy patients specifically, but the physiological rationale is supported by preclinical and mechanistic research.",
          },
          {
            q: "What's the difference between PT-141 and Vyleesi?",
            a: "Vyleesi is the FDA-approved, pharmaceutical-grade injectable formulation of bremelanotide for HSDD in premenopausal women. Research-grade PT-141 from peptide vendors is the same molecule produced for laboratory use. Purity, sterility, and dosing consistency vary significantly between pharmaceutical and research-grade sources.",
          },
          {
            q: "How does PT-141 compare to other post-RARP options?",
            a: "Current standard-of-care includes oral PDE5 inhibitors, intracavernosal injections (alprostadil), penile rehabilitation programs, and vacuum erection devices. PT-141 is not part of standard urological practice post-RARP; its potential relevance lies in its different mechanism of action for patients who don't respond adequately to PDE5 inhibitors. Any post-surgical sexual health protocol should be managed by a urologist.",
          },
          {
            q: "Is PT-141 being studied for prostate cancer survivors specifically?",
            a: "As of mid-2026, there are no published large-scale RCTs specifically evaluating PT-141 in post-RARP patients. The mechanistic rationale exists and melanocortin agonists are actively discussed in sexual medicine research, but dedicated prostate cancer survivor trials remain a gap in the published literature.",
          },
        ],
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "bpc-157-complete-guide",
    title: "BPC-157: The Complete Research Guide",
    excerpt:
      "A deep dive into Body Protection Compound-157 — mechanisms, studied benefits, and what the current literature says.",
    category: "Recovery",
    date: "April 2026",
    readTime: "8 min read",
    content: [
      {
        type: "intro",
        text: "BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has become one of the most widely studied peptides in regenerative research, with a growing body of preclinical literature documenting tissue-healing effects across multiple systems.",
      },
      {
        type: "h2",
        text: "What Is BPC-157?",
      },
      {
        type: "p",
        text: "BPC-157 is a 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) first isolated from human gastric juice. Unlike many peptides that target a single pathway, BPC-157 appears to interact with multiple biological systems simultaneously — which may explain its broad range of studied effects.",
      },
      {
        type: "h2",
        text: "Studied Benefits",
      },
      {
        type: "h3",
        text: "1. Tendon & Ligament Repair",
      },
      {
        type: "p",
        text: "Several animal studies have demonstrated accelerated healing of tendon-to-bone injuries with BPC-157 administration. Research published in the Journal of Physiology-Paris showed significant upregulation of growth hormone receptors in tendon fibroblasts, suggesting a direct mechanism for enhanced connective tissue repair.",
      },
      {
        type: "h3",
        text: "2. Gut Health & Mucosal Healing",
      },
      {
        type: "p",
        text: "Given its origin in gastric juice, it's unsurprising that BPC-157 shows strong effects on gastrointestinal tissue. Studies have shown protective effects against NSAID-induced damage, acceleration of intestinal anastomosis healing, and reduction of inflammatory bowel markers. This makes it one of the few peptides with compelling gut-specific research.",
      },
      {
        type: "h3",
        text: "3. Anti-Inflammatory Effects",
      },
      {
        type: "p",
        text: "BPC-157 has demonstrated the ability to modulate nitric oxide (NO) production and downregulate pro-inflammatory cytokines. Multiple studies show reductions in acute inflammation following musculoskeletal injuries in rodent models.",
      },
      {
        type: "h3",
        text: "4. Neurological Support",
      },
      {
        type: "p",
        text: "Emerging research suggests BPC-157 may support dopaminergic and serotonergic system function, with some studies showing neuroprotective effects following traumatic brain injury in animal models.",
      },
      {
        type: "h2",
        text: "Administration Routes Studied",
      },
      {
        type: "ul",
        items: [
          "Subcutaneous injection — most common in research settings",
          "Intramuscular injection — used for localized musculoskeletal studies",
          "Oral/intragastric — studied specifically for gut-related applications",
          "Topical — limited research, mostly for wound healing models",
        ],
      },
      {
        type: "h2",
        text: "What the Research Doesn't Cover",
      },
      {
        type: "p",
        text: "It's important to note that virtually all BPC-157 research to date has been conducted in rodent models. There are no completed human clinical trials as of this writing. While the animal data is consistently compelling, extrapolating these results to human physiology requires caution.",
      },
      {
        type: "callout",
        text: "BPC-157 has not been approved by the FDA for human use. All research on this compound is preclinical. This article is for informational and educational purposes only.",
      },
      {
        type: "h2",
        text: "Where to Source BPC-157 for Research",
      },
      {
        type: "p",
        text: "For legitimate research applications, purity and accurate dosing are critical. We recommend sourcing only from vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.",
      },
      {
        type: "cta",
        text: "View BPC-157 at Limitless Life Nootropics",
        productSlug: "bpc-157",
        vendor: "Limitless Life Nootropics",
        affiliateUrl: "https://limitlesslifenootropics.com/product/bpc-157?uid=17&oid=1&affid=10866",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "semaglutide-vs-tirzepatide",
    title: "Semaglutide vs. Tirzepatide: What the Research Shows",
    excerpt:
      "Comparing two of the most researched GLP-1 receptor agonists for body composition and metabolic health.",
    category: "Weight Management",
    date: "March 2026",
    readTime: "7 min read",
    content: [
      {
        type: "intro",
        text: "GLP-1 receptor agonists have fundamentally changed the metabolic research landscape. Semaglutide and tirzepatide are the two most studied compounds in this class — but they work through meaningfully different mechanisms. Here's what the literature actually shows.",
      },
      {
        type: "h2",
        text: "Mechanism of Action",
      },
      {
        type: "h3",
        text: "Semaglutide",
      },
      {
        type: "p",
        text: "Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the endogenous GLP-1 hormone, which is released after eating. Its primary effects include slowing gastric emptying, stimulating insulin secretion in a glucose-dependent manner, and suppressing glucagon release. The net result is reduced appetite, improved glycemic control, and significant reductions in body weight.",
      },
      {
        type: "h3",
        text: "Tirzepatide",
      },
      {
        type: "p",
        text: "Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual agonism appears to produce synergistic effects on insulin secretion, fat metabolism, and appetite suppression, which may explain its more pronounced effects in head-to-head comparisons.",
      },
      {
        type: "h2",
        text: "Head-to-Head: What Studies Show",
      },
      {
        type: "ul",
        items: [
          "SURMOUNT-5 trial: Tirzepatide produced ~20% greater weight loss than semaglutide in people with obesity",
          "Semaglutide (STEP trials): Average 15–17% body weight reduction over 68 weeks",
          "Tirzepatide (SURMOUNT trials): Average 20–22% body weight reduction over 72 weeks",
          "Both show significant cardiovascular risk reduction in large outcome trials",
          "Tirzepatide shows stronger HbA1c reduction in T2D populations",
        ],
      },
      {
        type: "h2",
        text: "Side Effect Profiles",
      },
      {
        type: "p",
        text: "Both compounds share a similar GI side effect profile — nausea, vomiting, and diarrhea are the most commonly reported, particularly during dose escalation. These effects typically diminish over time. Tirzepatide's GIP activity may modulate some of the GI tolerability seen with pure GLP-1 agonists, though clinical differences are modest.",
      },
      {
        type: "h2",
        text: "Which Is Right for Research?",
      },
      {
        type: "p",
        text: "The choice between semaglutide and tirzepatide for research purposes depends on the specific question being studied. Semaglutide has a longer research track record and more published data. Tirzepatide represents the current frontier of dual-agonist research and shows greater magnitude of effect in weight-focused studies.",
      },
      {
        type: "callout",
        text: "Neither semaglutide nor tirzepatide is approved for general use outside of specific medical indications. Research applications require appropriate institutional oversight.",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "cjc-1295-ipamorelin-stack",
    title: "CJC-1295 / Ipamorelin Stack: Growth Hormone Optimization",
    excerpt:
      "Why this combo has become the gold standard for GH-axis support in research settings.",
    category: "Growth & Performance",
    date: "March 2026",
    readTime: "6 min read",
    content: [
      {
        type: "intro",
        text: "Among growth hormone secretagogue combinations, CJC-1295 paired with Ipamorelin has emerged as one of the most researched and consistently cited stacks. The synergy between these two compounds — one a GHRH analogue, the other a selective ghrelin mimetic — produces robust, pulsatile GH release with a favorable safety profile compared to exogenous GH administration.",
      },
      {
        type: "h2",
        text: "Understanding Each Compound",
      },
      {
        type: "h3",
        text: "CJC-1295 (with DAC)",
      },
      {
        type: "p",
        text: "CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification extends its half-life from minutes to approximately 6–8 days by binding to serum albumin. This produces sustained elevation of baseline GH and IGF-1 levels rather than sharp pulses.",
      },
      {
        type: "h3",
        text: "Ipamorelin",
      },
      {
        type: "p",
        text: "Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR). It is notable for its high selectivity — it stimulates GH release without significantly elevating cortisol or prolactin, which distinguishes it from older GH secretagogues like GHRP-2 and GHRP-6.",
      },
      {
        type: "h2",
        text: "Why the Combination Works",
      },
      {
        type: "p",
        text: "CJC-1295 and Ipamorelin act on two distinct receptors within the GH axis — GHRH receptors and ghrelin receptors respectively. When combined, they produce a synergistic amplification of GH pulse amplitude. Research suggests the combination produces GH release 2–10x greater than either compound alone, while maintaining the physiological pulsatile pattern that exogenous GH disrupts.",
      },
      {
        type: "ul",
        items: [
          "CJC-1295 raises the baseline 'floor' of GH secretion",
          "Ipamorelin amplifies individual GH pulses",
          "Combined effect: higher amplitude pulses on an elevated baseline",
          "Preserves natural GH rhythm unlike exogenous HGH",
          "No significant cortisol or prolactin elevation (Ipamorelin selective)",
        ],
      },
      {
        type: "h2",
        text: "Studied Effects",
      },
      {
        type: "ul",
        items: [
          "Increased lean body mass in multiple animal models",
          "Reduction in adipose tissue in animal models, particularly visceral fat",
          "Improved sleep quality (GH is primarily secreted during slow-wave sleep)",
          "Enhanced recovery from exercise-induced muscle damage in preclinical studies",
          "Improved bone mineral density markers in aging models",
        ],
      },
      {
        type: "callout",
        text: "CJC-1295 and Ipamorelin are research compounds only. They have not been approved by the FDA for human use. All referenced effects are from preclinical studies.",
      },
      {
        type: "cta",
        text: "View CJC-1295 / Ipamorelin at Limitless Life Nootropics",
        productSlug: "cjc-1295-ipamorelin",
        vendor: "Limitless Life Nootropics",
        affiliateUrl: "https://limitlesslifenootropics.com/product/ipamorelin-cjc-1295-no-dac?uid=27&oid=1&affid=10866",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "best-peptides-for-weight-loss",
    title: "Best Peptides for Weight Loss: What the Research Shows",
    excerpt:
      "A research-backed breakdown of the most studied peptides for fat loss, appetite control, and metabolic optimization.",
    category: "Weight Management",
    date: "April 2026",
    readTime: "9 min read",
    content: [
      {
        type: "intro",
        text: "The peptide space has produced some of the most compelling weight management research in recent history. From GLP-1 receptor agonists to growth hormone secretagogues, several compounds have demonstrated significant fat loss effects in controlled studies. Here's what the evidence actually shows.",
      },
      {
        type: "h2",
        text: "1. Semaglutide — The Benchmark",
      },
      {
        type: "p",
        text: "Semaglutide remains the most clinically studied peptide for weight loss. As a GLP-1 receptor agonist, it works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving insulin sensitivity. The STEP trials showed an average of 15–17% body weight reduction over 68 weeks — results previously unseen outside of bariatric surgery.",
      },
      {
        type: "ul",
        items: [
          "15–17% average body weight reduction in STEP clinical trials",
          "Significant reduction in waist circumference and visceral fat",
          "Improved fasting glucose and HbA1c",
          "Cardiovascular risk reduction in SELECT trial",
        ],
      },
      {
        type: "h2",
        text: "2. CJC-1295 / Ipamorelin — Indirect Fat Loss via GH",
      },
      {
        type: "p",
        text: "Growth hormone has well-documented lipolytic effects — it directly stimulates the breakdown of stored fat (lipolysis) and inhibits fat storage. CJC-1295 paired with Ipamorelin produces sustained, physiological GH elevation that supports fat metabolism, particularly visceral and subcutaneous adipose tissue reduction.",
      },
      {
        type: "ul",
        items: [
          "GH-mediated lipolysis — direct fat cell breakdown",
          "Preferential loss of visceral fat in animal models",
          "Preservation of lean muscle mass during caloric restriction",
          "Improved insulin sensitivity over time",
        ],
      },
      {
        type: "cta",
        text: "View CJC-1295 / Ipamorelin at Limitless Life Nootropics",
        productSlug: "cjc-1295-ipamorelin",
        vendor: "Limitless Life Nootropics",
        affiliateUrl: "https://limitlesslifenootropics.com/product/ipamorelin-cjc-1295-no-dac?uid=27&oid=1&affid=10866",
      },
      {
        type: "h2",
        text: "3. BPC-157 — Supporting the Metabolic Environment",
      },
      {
        type: "p",
        text: "While BPC-157 is not a direct fat loss compound, its role in gut healing and metabolic regulation deserves mention in weight management research. Gut microbiome health and intestinal barrier integrity are increasingly recognized as critical factors in metabolic health and body composition. BPC-157's documented effects on gut mucosal healing may support an optimal metabolic environment.",
      },
      {
        type: "h2",
        text: "Stacking Considerations",
      },
      {
        type: "p",
        text: "Research contexts often combine compounds with complementary mechanisms. A GLP-1 agonist like semaglutide addresses appetite and insulin signaling, while a GH secretagogue stack addresses direct lipolysis and muscle preservation. These are distinct pathways that can theoretically be studied in combination — though this requires careful protocol design.",
      },
      {
        type: "callout",
        text: "All peptides discussed in this article are research compounds only. They are not approved for weight loss treatment and must not be used as substitutes for medical care. Consult a qualified physician for any weight management concerns.",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "peptides-for-libido-sexual-health",
    title: "Peptides for Libido & Sexual Health: PT-141 and Beyond",
    excerpt:
      "An evidence-based look at peptides studied for libido enhancement and sexual function in both men and women.",
    category: "Wellness",
    date: "April 2026",
    readTime: "7 min read",
    content: [
      {
        type: "intro",
        text: "Sexual health is a dimension of wellness that is increasingly being studied through the lens of peptide biology. Unlike traditional approaches that target hormones or vascular function, several peptides operate through central nervous system pathways — specifically the melanocortin system — to influence libido and sexual response at the neurological level.",
      },
      {
        type: "h2",
        text: "PT-141 (Bremelanotide) — The Most Studied",
      },
      {
        type: "p",
        text: "PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) and acts as a melanocortin receptor agonist — specifically at MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work primarily through vascular mechanisms, PT-141 activates the neural pathways that initiate sexual desire.",
      },
      {
        type: "ul",
        items: [
          "Acts centrally via melanocortin receptors — not vascular",
          "Studied in both male and female sexual dysfunction models",
          "FDA approved version (Vyleesi) exists for hypoactive sexual desire disorder in premenopausal women",
          "Studied for effects on sexual desire and arousal independent of hormonal status",
          "Effects reported within 45–60 minutes in clinical studies",
        ],
      },
      {
        type: "h3",
        text: "Research in Women",
      },
      {
        type: "p",
        text: "PT-141 has been studied in women with hypoactive sexual desire disorder (HSDD). Double-blind trials demonstrated statistically significant improvements in sexual desire scores compared to placebo. The central mechanism of action makes it particularly relevant for desire-phase dysfunction, which is distinct from arousal or physiological response issues.",
      },
      {
        type: "h3",
        text: "Research in Men",
      },
      {
        type: "p",
        text: "In men, PT-141 has been studied both as a standalone compound and in combination with PDE5 inhibitors. Research shows improvements in erectile function scores, with the central pathway providing benefit even in cases where vascular approaches are insufficient. The dual mechanism — central desire activation plus possible peripheral effects — makes it a distinctive research subject.",
      },
      {
        type: "h2",
        text: "The Role of BPC-157 in Sexual Health",
      },
      {
        type: "p",
        text: "BPC-157's nitric oxide modulating properties have generated interest in its potential role in vascular aspects of sexual function. Nitric oxide is a key mediator of penile erection and clitoral engorgement. While direct sexual health studies on BPC-157 are limited, its effects on NO pathways and vascular health represent an emerging area of research interest.",
      },
      {
        type: "h2",
        text: "Hormonal Context: Sermorelin and Testosterone",
      },
      {
        type: "p",
        text: "Growth hormone and IGF-1 play supporting roles in sexual health — they influence energy, mood, and hormonal balance. Sermorelin, as a GHRH analogue, stimulates natural GH production and has been studied in the context of age-related hormonal decline. In men with low GH status, restoration of GH levels has been associated with improvements in sexual function markers.",
      },
      {
        type: "h2",
        text: "Key Considerations for Researchers",
      },
      {
        type: "ul",
        items: [
          "PT-141 is the most directly studied peptide for sexual function",
          "Central vs. peripheral mechanisms are an important distinction in study design",
          "Hormonal baseline (testosterone, estrogen, GH) should be characterized in any study",
          "Nausea is the most commonly reported side effect of PT-141 in clinical trials",
          "Flushing and transient blood pressure changes have been observed at higher doses",
        ],
      },
      {
        type: "callout",
        text: "All compounds discussed are for research purposes only. Sexual health concerns should be addressed with a qualified healthcare professional. PT-141 (Vyleesi) is FDA-approved only for a specific indication in premenopausal women under medical supervision.",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
  {
    slug: "how-to-read-a-peptide-coa",
    title: "How to Read a Peptide Certificate of Analysis",
    excerpt:
      "A plain-English breakdown of what's in a COA, what to look for, and red flags to avoid.",
    category: "Buyer's Guide",
    date: "February 2026",
    readTime: "5 min read",
    content: [
      {
        type: "intro",
        text: "A Certificate of Analysis (COA) is the single most important document when evaluating a peptide vendor. It's the paper trail between a manufacturer's claims and independent verification. Yet most buyers don't know how to read one. This guide breaks it down.",
      },
      {
        type: "h2",
        text: "What a COA Should Include",
      },
      {
        type: "ul",
        items: [
          "Product name and lot/batch number",
          "Testing laboratory name and accreditation (look for ISO 17025)",
          "Test date (should be recent — within 12 months of purchase)",
          "HPLC purity result (High-Performance Liquid Chromatography)",
          "Mass spectrometry (MS) confirmation of molecular identity",
          "Amino acid composition or sequence confirmation",
          "Moisture content and residual solvent analysis (for lyophilized peptides)",
        ],
      },
      {
        type: "h2",
        text: "The Most Important Number: HPLC Purity",
      },
      {
        type: "p",
        text: "HPLC purity tells you what percentage of the sample is actually the peptide you ordered. Everything else is impurities — which could be related peptide fragments, synthesis byproducts, or in worst cases, entirely different compounds.",
      },
      {
        type: "ul",
        items: [
          "≥99% purity — pharmaceutical grade, ideal for sensitive research",
          "≥98% purity — research grade, acceptable for most applications",
          "95–98% purity — lower grade, use with caution",
          "Below 95% — do not use for any serious research application",
        ],
      },
      {
        type: "h2",
        text: "Mass Spectrometry: Confirming Identity",
      },
      {
        type: "p",
        text: "HPLC tells you how pure the sample is, but mass spectrometry (MS) tells you what it actually is. A COA with both HPLC and MS data is significantly more trustworthy than one with HPLC alone. Look for the reported molecular weight to match the theoretical molecular weight of the compound within a small margin (typically ±0.5 Da).",
      },
      {
        type: "h2",
        text: "Red Flags to Watch For",
      },
      {
        type: "ul",
        items: [
          "No third-party lab — in-house testing only means the vendor is grading their own work",
          "No lab name or accreditation on the COA",
          "COA older than 18 months — peptides degrade, testing should be recent",
          "Purity reported without a specific method (HPLC, MS, etc.)",
          "Generic COA not tied to a specific batch number",
          "COA available only on request — reputable vendors post them publicly",
        ],
      },
      {
        type: "h2",
        text: "How Aura Protocols Vets Vendors",
      },
      {
        type: "p",
        text: "Every vendor we feature on Aura Protocols must provide publicly accessible, batch-specific COAs from accredited third-party laboratories. We manually review these documents before listing any product. If a vendor's documentation doesn't meet our standards, they don't appear on this site — regardless of commission rates.",
      },
      {
        type: "callout",
        text: "When in doubt, email the vendor and ask for the COA for the specific batch you're purchasing. A trustworthy vendor will respond promptly with complete documentation.",
      },
      {
        type: "disclaimer",
        text: "This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.",
      },
    ],
  },
];
